NMR study of alkaloids. V.13C NMR spectra and reconsideration of the structures of 11- and 10-hydroxypleiocarpamines and the structures of new alkaloids fromVinca erecta
The structures of phenolic alkaloids isolated previously fromVinca erecta Rgl. et Schmalh. have been reconsidered on the basis of the results of a study of their13C NMR spectra, and it has been shown that a base with mp 228–229° has the structure of 11-hydroxystrictamine and an amorphous base of the same composition isomeric with it is 10-hydroxystrictamine. The structures of two new indolenine alkaloids — ercinamine and ercinaminine — have been determined from an analysis of13C NMR spectra, and also on the basis of PMR and IR spectra and chemical transformations.
Gardneria alkaloids. XII. Carbon magnetic resonance spectra of gardneria alkaloids. A study on the configuration of the side chain double bonds of indole alkaloids.
^ C-NMR spectra of several Gardneria alkaloids and their derivatives were studied. The chemical shifts of C(15) and C(21) were found to be diagnostic for the configuration of the side chain double bonds between C(19) and C(20). As a result of the present study the E configuration of the ethylidene side chain of chitosenine (V) was confirmed.
Botulinum toxin in the management of chronic migraine: clinical evidence and experience
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.